NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy - Trial NCT06403267
Access comprehensive clinical trial information for NCT06403267 through Pure Global AI's free database. This Phase 2 trial is sponsored by NoNO Inc. and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NoNO Inc.
Timeline & Enrollment
Phase 2
May 01, 2024
May 01, 2026
Primary Outcome
Reducing global disability in participants with acute ischemic stroke (AIS)
Summary
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).
 
 This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint
 (PROBE) controlled single-dose adaptive trial.
 
 A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute
 ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular
 thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403267
Non-Device Trial